Emma Chávez-Manzanera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emma Chávez-Manzanera has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Cantú-Brito
Department of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
2 shared publications - Erwin Chiquete
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
2 shared publications - Martha Kaufer-Horwitz
Obesity and Eating Disorders Clinic, Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
2 shared publications - María de Los Ángeles Vargas-Martínez
Department of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
2 shared publications - Simón Barquera
Nutrition and Health Research Center, National Institute of Public Health, Cuernavaca, Mexico
2 shared publications - Verónica Vázquez-Velázquez
Obesity and Eating Disorders Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
2 shared publications
Latest Publications
- Open Access
- 7 January 2026
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 55, 101366
Impact and scope of Mexican clinical practice guideline for adult overweight and obesity on weight stigma
- 7 January 2026
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 55, 101366
Open AccessImpact and scope of Mexican clinical practice guideline for adult overweight and obesity on weight stigma
- Open Access
- 2 July 2025
- Published by Springer Nature in Reviews in Endocrine and Metabolic Disorders
- Vol. 26 (5) , 745-758
Emerging evidence and potential avenues to achieve durable outcomes in patients with obesity: the confluence of nutrition, and Microbiome on body composition
Obesity is a global health concern that impacts health, quality of life, and longevity in affected individuals. Comorbid cardiovascular disease, type 2 diabetes, cancer, and other conditions often accompany obesity, and researchers are actively investigating therapeutic strategies to treat obesity and mitigate the health risks associated with excess adiposity. Restrictive nutritional intake and body weight reduction through lifestyle behavioral interventions, bariatric procedures, and highly effective anti-obesity medications are all recommended treatments for obesity. Meanwhile, the caloric restriction that comes with very low-calorie diets can result in changes in body composition, most notably a progressive loss of muscle mass and/or functionality, a process that can be accelerated by aging, underlying metabolic disease, or inadequate protein intake seen with many dietary patterns. While muscle loss was previously understood as a condition only affecting older individuals, this outcome is common in patients with obesity. The term sarcopenic obesity has been used to refer to this condition, and it is now recognized as an important potential complication in all patients with obesity. Dietary challenges that influence overall body composition also have drawn attention to the gut microbiome, a topic of growing interest as there is an increasingly recognized interplay between diet, the metabolic actions of microorganisms in the gut that impact macronutrient and micronutrient production and absorption, and human health. This article will review the current understanding of obesity as a chronic disease, the impact of diet and nutritional therapy on body composition, and the potential relevance of the gut microbiome in this setting.
- 2 July 2025
- Published by Springer Nature in Reviews in Endocrine and Metabolic Disorders
- Vol. 26 (5) , 745-758
Open AccessEmerging evidence and potential avenues to achieve durable outcomes in patients with obesity: the confluence of nutrition, and Microbiome on body composition
Obesity is a global health concern that impacts health, quality of life, and longevity in affected individuals. Comorbid cardiovascular disease, type 2 diabetes, cancer, and other conditions often accompany obesity, and researchers are actively investigating therapeutic strategies to treat obesity and mitigate the health risks associated with excess adiposity. Restrictive nutritional intake and body weight reduction through lifestyle behavioral interventions, bariatric procedures, and highly effective anti-obesity medications are all recommended treatments for obesity. Meanwhile, the caloric restriction that comes with very low-calorie diets can result in changes in body composition, most notably a progressive loss of muscle mass and/or functionality, a process that can be accelerated by aging, underlying metabolic disease, or inadequate protein intake seen with many dietary patterns. While muscle loss was previously understood as a condition only affecting older individuals, this outcome is common in patients with obesity. The term sarcopenic obesity has been used to refer to this condition, and it is now recognized as an important potential complication in all patients with obesity. Dietary challenges that influence overall body composition also have drawn attention to the gut microbiome, a topic of growing interest as there is an increasingly recognized interplay between diet, the metabolic actions of microorganisms in the gut that impact macronutrient and micronutrient production and absorption, and human health. This article will review the current understanding of obesity as a chronic disease, the impact of diet and nutritional therapy on body composition, and the potential relevance of the gut microbiome in this setting.
- Open Access
- 2 October 2024
- Published by Springer Nature in Current Obesity Reports
- Vol. 13 (4) , 643-666
Mexican Clinical Practice Guidelines for Adult Overweight and Obesity Management
Purpose To develop Mexico’s first methodologically rigorous clinical practice guideline for the management of adult overweight and obesity. The target audiences are interdisciplinary healthcare professionals across healthcare systems who are the first point of contact for patients with obesity in Mexico, patients, and health system decision makers. Recent Findings A review of recent international obesity clinical practice guidelines and an expert consensus process identified: i) common recommendations appropriate for implementation in Mexico and ii) knowledge gaps requiring the formulation of new recommendations. In all, 20 new recommendations and 20 good practice statements were developed using the GRADE Evidence-to-Decision Framework and expert consensus. Summary Overweight and obesity negatively impact the health and well-being of individuals and populations in Mexico. This guideline aims to establish a new evidence-based, patient-centered, non-stigmatizing, and practical treatment and management framework, based on the fundamental principles of chronic disease prevention and management.
- 2 October 2024
- Published by Springer Nature in Current Obesity Reports
- Vol. 13 (4) , 643-666
Open AccessMexican Clinical Practice Guidelines for Adult Overweight and Obesity Management
Purpose To develop Mexico’s first methodologically rigorous clinical practice guideline for the management of adult overweight and obesity. The target audiences are interdisciplinary healthcare professionals across healthcare systems who are the first point of contact for patients with obesity in Mexico, patients, and health system decision makers. Recent Findings A review of recent international obesity clinical practice guidelines and an expert consensus process identified: i) common recommendations appropriate for implementation in Mexico and ii) knowledge gaps requiring the formulation of new recommendations. In all, 20 new recommendations and 20 good practice statements were developed using the GRADE Evidence-to-Decision Framework and expert consensus. Summary Overweight and obesity negatively impact the health and well-being of individuals and populations in Mexico. This guideline aims to establish a new evidence-based, patient-centered, non-stigmatizing, and practical treatment and management framework, based on the fundamental principles of chronic disease prevention and management.
- Open Access
- 22 August 2024
- Published by Instituto Nacional de Salud Publica in Salud Pública de México
- Vol. 66 (4, jul-ago) , 414-424
Obesidad en adultos
Objetivo. Describir la prevalencia de obesidad en adultos de la Encuesta Nacional de Salud y Nutrición Continua 2020-2023 (Ensanut Continua 2020-2023), sus principales características sociodemográficas, su asociación con enfermedades crónicas, factores de riesgo y consumo de bebidas energéticas industrializadas (BEI), así como las tendencias en los últimos 23 años, para contribuir en la generación de evidencia para el diseño de políticas de salud pública. Material y métodos. Se analizó la información de 32 889 participantes para caracterizar a la población adulta mexicana por grupos de índice de masa corporal (IMC) y estratificados por variables sociodemográficas. Se usaron modelos de regresión logística para estimar las asociaciones de esos grupos con las variables de interés. Finalmente, se exploró la tendencia de los grupos de IMC en las últimas seis encuestas nacionales (2000-2023). Resultados. La prevalencia de obesidad en adultos fue 37.1% (41.0% mujeres, 33.0% hombres). El porcentaje de energía proveniente de BEI fue el doble en hombres que en mujeres (6.8 vs. 3.3%). Los hombres del cuartil más alto del porcentaje de energía proveniente de BEI tuvieron 2.29 veces mayor posibilidad de tener obesidad (p0.05). Conclusiones. La prevalencia nacional de obesidad en adultos mostró un incremento de 41.7% en el periodo 2000-2016. A partir del 2016 hubo una estabilización de la tendencia. El alto consumo de BEI aumenta la posibilidad de tener obesidad. Se requieren intervenciones con una visión integral y multisistémica que permitan la prevención y control de la obesidad.
- 22 August 2024
- Published by Instituto Nacional de Salud Publica in Salud Pública de México
- Vol. 66 (4, jul-ago) , 414-424
Open AccessObesidad en adultos
Objetivo. Describir la prevalencia de obesidad en adultos de la Encuesta Nacional de Salud y Nutrición Continua 2020-2023 (Ensanut Continua 2020-2023), sus principales características sociodemográficas, su asociación con enfermedades crónicas, factores de riesgo y consumo de bebidas energéticas industrializadas (BEI), así como las tendencias en los últimos 23 años, para contribuir en la generación de evidencia para el diseño de políticas de salud pública. Material y métodos. Se analizó la información de 32 889 participantes para caracterizar a la población adulta mexicana por grupos de índice de masa corporal (IMC) y estratificados por variables sociodemográficas. Se usaron modelos de regresión logística para estimar las asociaciones de esos grupos con las variables de interés. Finalmente, se exploró la tendencia de los grupos de IMC en las últimas seis encuestas nacionales (2000-2023). Resultados. La prevalencia de obesidad en adultos fue 37.1% (41.0% mujeres, 33.0% hombres). El porcentaje de energía proveniente de BEI fue el doble en hombres que en mujeres (6.8 vs. 3.3%). Los hombres del cuartil más alto del porcentaje de energía proveniente de BEI tuvieron 2.29 veces mayor posibilidad de tener obesidad (p0.05). Conclusiones. La prevalencia nacional de obesidad en adultos mostró un incremento de 41.7% en el periodo 2000-2016. A partir del 2016 hubo una estabilización de la tendencia. El alto consumo de BEI aumenta la posibilidad de tener obesidad. Se requieren intervenciones con una visión integral y multisistémica que permitan la prevención y control de la obesidad.
- Open Access
- 1 June 2024
- Published by Sociedad Dominicana de Endocrinología y Nutrición in Hormonas (Archivos Dominicanos de Endocrinología)
- Vol. 15 (1) , 27-34
Reflexiones sobre el tratamiento farmacológicopara obesidad
La obesidad es una enfermedad crónica de origen multifactorial, caracterizada por múltiples recaídas en el transcurso de la vida del individuo que la padece. El mantenimiento del peso perdido a largo plazo es un desafío, debido a que la ganancia de este es común después de haber alcanzado una pérdida de peso exitosa. La farmacoterapia para obesidad junto con las intervenciones en el estilo de vida aumenta la proporción de individuos que alcanzan un mayor éxito a largo plazo en el mantenimiento del peso perdido y en el control de comorbilidades. Previo a la prescripción del tratamiento farmacológico, los profesionales de la salud deben considerar las características clínicas de cada paciente y los perfiles de seguridad de cada fármaco con la finalidad de indivi- dualizar los tratamientos.
- 1 June 2024
- Published by Sociedad Dominicana de Endocrinología y Nutrición in Hormonas (Archivos Dominicanos de Endocrinología)
- Vol. 15 (1) , 27-34
Open AccessReflexiones sobre el tratamiento farmacológicopara obesidad
La obesidad es una enfermedad crónica de origen multifactorial, caracterizada por múltiples recaídas en el transcurso de la vida del individuo que la padece. El mantenimiento del peso perdido a largo plazo es un desafío, debido a que la ganancia de este es común después de haber alcanzado una pérdida de peso exitosa. La farmacoterapia para obesidad junto con las intervenciones en el estilo de vida aumenta la proporción de individuos que alcanzan un mayor éxito a largo plazo en el mantenimiento del peso perdido y en el control de comorbilidades. Previo a la prescripción del tratamiento farmacológico, los profesionales de la salud deben considerar las características clínicas de cada paciente y los perfiles de seguridad de cada fármaco con la finalidad de indivi- dualizar los tratamientos.
- Open Access
- 17 April 2022
- Published by MDPI AG in Brain Sciences
- Vol. 12 (4) , 509
Influence of Weight Loss on Cognitive Functions: A Pilot Study of a Multidisciplinary Intervention Program for Obesity Treatment
There is a relationship between obesity and cognitive functioning. Our aim was to assess weight loss influence on global cognition and executive functioning (EF) in adults with obesity under a multidisciplinary weight loss program. In this six-month longitudinal study, we assessed 81 adults (age < 50 years) with body mass index (BMI) ≥ 30. EF and global cognitive performance were evaluated with the Montreal Cognitive Assessment (MoCA), Neuropsychological Battery of Executive Functions (BANFE-2) and Trail Making Test-Part B (TMT-B). Median age was 40.0 years (IQR: 31.5–47, 61% women), and the median BMI was 41.4 (IQR: 36.7–45.9). At a six-month follow-up, the mean weight loss was 2.67% (29.6% of patients achieved ≥5% weight loss). There was an improvement in EF evaluated with BANFE (p = 0.0024) and global cognition with MoCA (p = 0.0024). Women experienced more remarkable change, especially in EF. Weight loss did not correlate with cognitive performance, except for TMT-B (r-0.258, p = 0.026). In the regression analysis, only years of education predicted the MoCA score. This study showed that patients improved cognitive performance during the follow-up; nevertheless, the magnitude of weight loss did not correlate with cognitive improvement. Future studies are warranted to demonstrate if patients achieving ≥5% weight loss can improve cognition, secondary to weight loss.
- 17 April 2022
- Published by MDPI AG in Brain Sciences
- Vol. 12 (4) , 509
Open AccessInfluence of Weight Loss on Cognitive Functions: A Pilot Study of a Multidisciplinary Intervention Program for Obesity Treatment
There is a relationship between obesity and cognitive functioning. Our aim was to assess weight loss influence on global cognition and executive functioning (EF) in adults with obesity under a multidisciplinary weight loss program. In this six-month longitudinal study, we assessed 81 adults (age < 50 years) with body mass index (BMI) ≥ 30. EF and global cognitive performance were evaluated with the Montreal Cognitive Assessment (MoCA), Neuropsychological Battery of Executive Functions (BANFE-2) and Trail Making Test-Part B (TMT-B). Median age was 40.0 years (IQR: 31.5–47, 61% women), and the median BMI was 41.4 (IQR: 36.7–45.9). At a six-month follow-up, the mean weight loss was 2.67% (29.6% of patients achieved ≥5% weight loss). There was an improvement in EF evaluated with BANFE (p = 0.0024) and global cognition with MoCA (p = 0.0024). Women experienced more remarkable change, especially in EF. Weight loss did not correlate with cognitive performance, except for TMT-B (r-0.258, p = 0.026). In the regression analysis, only years of education predicted the MoCA score. This study showed that patients improved cognitive performance during the follow-up; nevertheless, the magnitude of weight loss did not correlate with cognitive improvement. Future studies are warranted to demonstrate if patients achieving ≥5% weight loss can improve cognition, secondary to weight loss.
- 13 January 2022
- Published by Springer Nature in Neurological Sciences
- Vol. 43 (4) , 2217-2229
Critical role of acute hypoxemia on the cognitive impairment after severe COVID-19 pneumonia: a multivariate causality model analysis
Background A high proportion of coronavirus disease 2019 (COVID-19) survivors may develop long-term cognitive impairment. We aimed to develop a multivariate causal model exposing the links between COVID-19-associated biomarkers, illness-related variables, and their effects on cognitive performance. Methods In this prospective study, we assess the potential drivers for the development of cognitive impairment in patients with severe COVID-19 pneumonia aged ≥ 18 years at 6-month follow-up after hospital discharge, using the Montreal Cognitive Assessment (MoCA). Patients with pre-existing cognitive impairment were excluded. Laboratory results at hospital admission were clustered by principal component analysis (PCA) and included in a path analysis model evaluating the causal relationship between age, comorbidities, hypoxemia, invasive mechanical ventilation (IMV) requirement, in-hospital delirium, and cognitive performance. Results We studied 92 patients: 54 (58.7%) men and 38 (41.3%) women, with median age of 50 years (interquartile range 42–55), among whom 50 (54.4%) tested positive for cognitive impairment at 6-month follow-up. Path analysis revealed a direct link between the thrombo-inflammatory component of PCA (C-reactive protein, fibrinogen, and neutrophils) and hypoxemia severity at hospital admission. Our model showed that low PaO2/FiO2 ratio values, unlike the thrombo-inflammatory component, had a direct effect on cognitive performance, independent from age, in-hospital delirium, and invasive mechanical ventilation. Conclusion In this study, biomarkers of thrombo-inflammation in COVID-19 and low PaO2/FiO2 had a negative effect on cognitive performance 6 months after hospital discharge. These results highlight the critical role of hypoxemia as a driver for impaired cognition in the mid-term.
- 13 January 2022
- Published by Springer Nature in Neurological Sciences
- Vol. 43 (4) , 2217-2229
Critical role of acute hypoxemia on the cognitive impairment after severe COVID-19 pneumonia: a multivariate causality model analysis
Background A high proportion of coronavirus disease 2019 (COVID-19) survivors may develop long-term cognitive impairment. We aimed to develop a multivariate causal model exposing the links between COVID-19-associated biomarkers, illness-related variables, and their effects on cognitive performance. Methods In this prospective study, we assess the potential drivers for the development of cognitive impairment in patients with severe COVID-19 pneumonia aged ≥ 18 years at 6-month follow-up after hospital discharge, using the Montreal Cognitive Assessment (MoCA). Patients with pre-existing cognitive impairment were excluded. Laboratory results at hospital admission were clustered by principal component analysis (PCA) and included in a path analysis model evaluating the causal relationship between age, comorbidities, hypoxemia, invasive mechanical ventilation (IMV) requirement, in-hospital delirium, and cognitive performance. Results We studied 92 patients: 54 (58.7%) men and 38 (41.3%) women, with median age of 50 years (interquartile range 42–55), among whom 50 (54.4%) tested positive for cognitive impairment at 6-month follow-up. Path analysis revealed a direct link between the thrombo-inflammatory component of PCA (C-reactive protein, fibrinogen, and neutrophils) and hypoxemia severity at hospital admission. Our model showed that low PaO2/FiO2 ratio values, unlike the thrombo-inflammatory component, had a direct effect on cognitive performance, independent from age, in-hospital delirium, and invasive mechanical ventilation. Conclusion In this study, biomarkers of thrombo-inflammation in COVID-19 and low PaO2/FiO2 had a negative effect on cognitive performance 6 months after hospital discharge. These results highlight the critical role of hypoxemia as a driver for impaired cognition in the mid-term.